Grifols SA
- Last sale
- Nov 6, 2026 · -0.47%
- Market cap
- —
- no share count on file
- Filings
- 463
FY 2024+9.4% FY24 yoy
FY 2024+270.8% FY24 yoy
FY 2024+52.4% FY24 yoy
FY 2024derivedN/M FY24 yoy
FY 2024+283.3% FY24 yoy
FY 2024+85.0% FY24 yoy
Price
Nov 6, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2024 | 2024-12-31 | €7,212,382,000 | reported | |
| FY 2023 | 2023-12-31 | €6,591,977,000 | reported | |
| FY 2022 | 2022-12-31 | €6,063,967,000 | reported | |
| FY 2021 | 2021-12-31 | €4,933,118,000 | reported | |
| FY 2020 | 2020-12-31 | €5,340,038,000 | reported | |
| FY 2019 | 2019-12-31 | €5,098,691,000 | reported | |
| FY 2018 | 2018-12-31 | €4,486,724,000 | reported | |
| FY 2017 | 2017-12-31 | €4,318,073,000 | reported | |
| FY 2016 | 2016-12-31 | €4,049,830,000 | reported | |
| FY 2015 | 2015-12-31 | €3,934,563,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2024 | €962.00K | — | €962.00K | — | — | — | 0.1% |
| FY2023 | €0.00 | €0.00 | €0.00 | — | — | — | — |
| FY2022 | €592.00K | €3.46M | €4.05M | — | — | — | — |
| FY2021 | €258.95M | €125.70M | €384.65M | — | — | — | 110.0% |
| FY2020 | €113.23M | — | €113.23M | — | — | — | 13.6% |
Segments
LineFY2025ShareChange
Biopharma€6.49B86%+5.6%
Diagnostic€640.00M8.5%−0.8%
All Other Segments€243.00M3.2%+16.8%
Bio Supplies€154.00M2.0%−28.7%
Total€7.52B
Pharmaceutical preparations
552 covered companies are filed under this code. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
JNJJohnson & Johnson$94.2B6.0%28.5%$682.6BLLYEli Lilly & Co$65.2B44.7%31.7%$1.3TMRKMerck & Co., Inc.$65.0B1.3%28.1%$362.3BPFEPfizer Inc$62.6B1.6%12.4%$164.3BABBVAbbVie Inc.$61.2B8.6%6.9%$520.5BAZNAstraZeneca PLC$58.7B8.6%17.4%—BMYBristol Myers Squibb Co$48.2B0.2%14.6%$127.4BABTAbbott Laboratories$44.3B5.7%14.7%$185.8B
GRFSGrifols SA (this company)————
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, largest by revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Grifols SA · CIK 1438569 · Engraved from SEC EDGAR